HC Wainwright Reaffirms Buy Rating for Acurx Pharmaceuticals (NASDAQ:ACXP)

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $31.00.

Acurx Pharmaceuticals Price Performance

Shares of ACXP stock traded down $0.04 on Tuesday, reaching $1.31. 122,902 shares of the company were exchanged, compared to its average volume of 1,112,144. The company has a market cap of $7.26 million, a price-to-earnings ratio of -0.49 and a beta of -2.02. Acurx Pharmaceuticals has a one year low of $1.27 and a one year high of $8.34. The company has a 50-day moving average of $1.43 and a 200-day moving average of $2.08.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.15). As a group, sell-side analysts predict that Acurx Pharmaceuticals will post -2 EPS for the current year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.